Clinical Trial Results: A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and tolerability of maralixibat in infants with cholestatic liver diseases including PFIC and Alagille syndrome; results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alagille Syndrome
• Progressive Familial Intrahepatic Cholestasis

Drugs mentioned

• Maralixibat (maralixibat)

Snippet

Sponsor: Mirum Pharmaceuticals, Inc. | Conditions: Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2026-06-02